PRANDIMET
LOE ApproachingNDAORALTABLET
Approved
Jun 2008
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PRANDIMET is an oral small-molecule tablet approved by FDA in June 2008 for diabetes management. The product is a fixed-dose combination indicated for type 2 diabetes, combining two distinct pharmacologic mechanisms to improve glycemic control. It represents a combination therapy approach to diabetes care.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), indicating potential team consolidation and shift toward managed decline strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
PRANDIMET offers limited career growth opportunities given its LOE-approaching status and zero linked job openings. Roles on this product focus on managing decline, protecting remaining market share, and optimizing profitability rather than innovation or expansion.
Brand ManagerField Sales Representative
Worked on PRANDIMET at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.